These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25995429)

  • 1. Kidney cancer: current and novel treatment options.
    Jonasch E
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):679-81. PubMed ID: 25995429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
    Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
    Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?
    Escudier B; Staehler M
    Eur Urol; 2018 Jan; 73(1):1-3. PubMed ID: 28890247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma.
    Ghatalia P; Zibelman MR; Geynisman DM; Plimack ER
    Clin Adv Hematol Oncol; 2018 Oct; 16(10):677-686. PubMed ID: 30543598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective.
    Choueiri TK
    Curr Clin Pharmacol; 2011 Aug; 6(3):164-8. PubMed ID: 21827394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in the treatment of renal cell carcinoma.
    Pezaro C; Davis ID
    Curr Med Chem; 2008; 15(12):1166-74. PubMed ID: 18473811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?
    Peyraud F; Larroquette M; Ravaud A; Gross-Goupil M
    Eur Urol; 2021 Sep; 80(3):269-274. PubMed ID: 33810923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic therapy in renal cell cancer.
    Srinivasan R; Armstrong AJ; Dahut W; George DJ
    BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF inhibitors in renal cell carcinoma.
    Vachhani P; George S
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):1016-1028. PubMed ID: 28212363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for non-clear cell histologies in renal cancer.
    Bitting RL; Madden J; Armstrong AJ
    Curr Clin Pharmacol; 2011 Aug; 6(3):169-80. PubMed ID: 21861801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
    Hirsch L; Flippot R; Escudier B; Albiges L
    Drugs; 2020 Aug; 80(12):1169-1181. PubMed ID: 32601914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
    Choueiri TK; Bukowski RM; Rini BI
    Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents.
    Choueiri TK
    Clin Genitourin Cancer; 2008 Mar; 6(1):15-20. PubMed ID: 18501077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to antiangiogenic therapies.
    Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
    Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies for renal cell carcinoma.
    Syed S; Tolcher AW
    Cancer Treat Res; 2003; 116():227-38. PubMed ID: 14650836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.